Thus, we speculate that the pathophysiological mechanism of MetS‐BPH may be through CYP19A1 SNPs, especially through increased genotype TT of rs700518 gene expression, which promotes the conversion of estrogen, leading to decreased T/E ratio; this triggers IR, leading to the occurrence of MetS‐BPH. The gene discussed is CYP19A1; the disease is benign prostatic hyperplasia.